| Product Name | eNOS ELISA kit (Human) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Nitric Oxide Synthase 3, Endothelial (NOS3). No significant cross-reactivity or interference between Nitric Oxide Synthase 3, Endothelial (NOS3) and analogues was observed. |
| Synonyms | NOS3; ECNOS; NOS III; E-NOS; C-NOS; ENOS; CNOS; Constitutive NOS; Nitric Oxide Synthase 3, Endothelial |
| Method | Sandwich |
| Detection Range | 0.156-10ng/mL |
| Sensitivity | 0.057ng/mL |
| Target | eNOS |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Endothelial NOS (eNOS). No significant cross-reactivity or interference between Endothelial NOS (eNOS) and analogues was observed. |
| Reactivity | Human |
| Sample Types | Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 100uL standard or sample to each well.Incubate 2 hours at 37℃; 3.Aspirate and add 100uL prepared Detection Reagent A.Incubate 1 hour at 37℃; 4.Aspirate and wash 3 times; 5.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 6.Aspirate and wash 5 times; 7.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 8.Add 50uL Stop Solution.Read at 450nm immediately. |
| Uniprot | P29474 |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | Inflammation influence on the formation of endothelial dysfunction in hypertensive patients caused by obesity;SIRT1 Gene Polymorphisms Affect the Protein Expression in Cardiovascular Diseases;Soluble Lectin-Like Oxidized LDL Receptor 1 as a Possible Mediator of Endothelial Dysfunction in Patients With Metabolic Syndrome;Chemerin plays a protective role by regulating human umbilical vein endothelial cell-induced nitric oxide signaling in preeclampsia;A Remarkable Age-Related Increase in SIRT1 Protein Expression against Oxidative Stress in Elderly:;Mutant DD genotype of NFKB1 gene is associated with the susceptibility and severity of coronary artery disease.;ThE REmOdELINg Of LEfT ATRIUm ANd vAsOdILATION fAcTORs chANgEs IN IschEmIc hEART fAILURE;Endothelial nitric oxide synthase deficiency influences normal cell cycle progression andapoptosis in trabecular meshwork cells.;SIRT1 inhibits releases of HMGB1 and HSP70 from human umbilical vein endothelial cells caused by IL-6 and the serum from a preeclampsia patient and protects the cells from death.;SIRT1 inhibits releases of HMGB1 and HSP70 from human umbilical vein endothelial cells caused by IL-6 and the serum from a preeclampsia patient and protects the cells from death;THE INFLUENCE OF THE ADDITIONAL USAGE OF L-ARGININE ON THE FACTORS OF VASODILATION AND THE CLINICAL DATA, COMPLICATED WITH CARDIAC DECOMPENSATION WITH REDUCED AND PRESERVED FRACTURE OF THE LEFT VENTRICLE THAT PATIENTS WITH STABLE CORONARY HEART DISEASE HAVE;Blunted Nitric Oxide Regulation in Tibetans under High Altitude Hypoxia;Effect of statins on sirtuin 1 and endothelial nitric oxide synthase expression in young patients with a history of premature myocardial infarction;Stężenia śródbłonkowej i indukowalnej formy syntazy tlenku azotu w surowicy krwi kobiet ciężarnych palących tytoń–badania wstępne;Influence of Active Exposure to Tobacco Smoke on Nitric Oxide Status of Pregnant Women;Premature Myocardial Infarction: Genetic Variations in SIRT1 Affect Disease Susceptibility;Silica nanoparticles trigger the vascular endothelial dysfunction and prethrombotic state via miR-451 directly regulating the IL6R signaling pathway;Динамика показателей эндотелиальной дисфункции до и после операции у больных варикозной болезнью нижних конечностей;Circadian fluctuations of endothelial nitric oxide synthase activity in females with rheumatoid arthritis: a pilot study;Circadian rhythms of endothelial nitric oxide synthase and toll-like receptors 2 production in females with rheumatoid arthritis depending on NOS3 gene polymorphism …;ASSOCIATIONS BETWEEN EFFICACY OF THE THERAPY AND CIRCADIAN FLUCTUATIONS OF ENDOTHELIAL NITRIC OXIDE SYNTHASE WITH TOLL-LIKE …;Dynamics of endothelial dysfunction indices before and after operation in patients with varicose disease of the lower extremities;Angiogenic factors measured in aspirated placental tissue between the 10+ 6 and 18+ 3 weeks of gestation;Serum inducible and endothelial nitric oxide synthase in coronary artery disease patients with Type 2 Diabetes mellitus; |
| Supplier | Cloud Clone |
PROTOCOLS:
SEA868Hu All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
